Stergiou Angelos M.
Known title: President and CEOCIK: 0001724253
Associated companies
Transaction History
| SLS | ▲ Buy | Grant | 1,065,000 | $0 | 6/16/2026 | View on chart |
| SLS | ▼ Sell | Other | 187,066 | $281K | 12/3/2025 | View on chart |
| SLS | ▲ Buy | Grant | 243,900 | $0 | 1/10/2025 | View on chart |
| SLS | ▲ Buy | Grant | 257,000 | $0 | 1/10/2025 | View on chart |
| SLS | ▼ Sell | Other | 28,289 | $32K | 12/4/2024 | View on chart |
| SLS | ▲ Buy | Grant | 159,000 | $0 | 1/22/2024 | View on chart |
| SLS | ▼ Sell | Other | 12,268 | $13K | 12/6/2023 | View on chart |
| SLS | ▲ Buy | Grant | 58,000 | $0 | 2/2/2023 | View on chart |
| SLS | ▼ Sell | Open Market | 6,494 | $17K | 12/5/2022 | View on chart |
| SLS | ▲ Buy | Grant | 44,000 | $0 | 1/31/2022 | View on chart |
| SLS | ▼ Sell | Open Market | 2,120 | $13K | 12/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SLS Stock Fluctuates Amid M&A Speculation and New AML Study
SELLAS Life Sciences shares have seen volatile movement driven by retail investor speculation about potential M&A activity at the ASH conference. Recent news also highlights a new AML study that has fueled optimism among some investors regarding the company's pipeline. While the stock has experienced a recent rally, momentum has slowed, leaving it trading well below the average analyst target price.
SLS Stock Fluctuates Amid M&A Speculation and New AML Study. SELLAS Life Sciences shares have seen volatile movement driven by retail investor speculation about potential M&A activity at the ASH conference. Recent news also highlights a new AML study that has fueled optimism among some investors regarding the company's pipeline. While the stock has experienced a recent rally, momentum has slowed, leaving it trading well below the average analyst target price.